Clinical Trials Logo

Clinical Trial Summary

The objective of this double-blind, parallel, randomized placebo-controlled clinical trial is to evaluate the effects of consumption of polyphenol-rich cranberry extract standardized in PACs (36 mg PACs/capsule) on cardiometabolic and neurocognitive health in women and men presenting abdominal obesity over an 8-week intervention period. The study will be conducted at Quebec Heart and Lung Institute - Laval University. The study will involve a total of 60 adult men and women presenting abdominal obesity. Included participants will be randomly assigned to the consumption of a cranberry extract or a placebo at a rate of one capsule per day for 8 weeks (56 days). The main outcomes are changes in metabolic profile, neurocognitive performance as well as brain structure and function following polyphenol-rich cranberry extract standardized in PACs compared with the placebo.

Clinical Trial Description

Background : Abdominal obesity is associated with impaired cognitive function and increased risk of neurodegenerative diseases. The metabolic disorders associated with obesity may lead to alterations in brain function and structure, explaining the link between obesity and some cognitive dysfunction. Magnetic resonance imaging (MRI) studies show that obese individuals are characterized by gray matter atrophy in brain regions involved in self-control. Atrophy and alteration of white matter fibers have also been observed in these individuals. However, the mechanisms explaining these changes are not yet elucidated. It has been suggested that metabolic and inflammatory alterations associated with abdominal obesity may lead to these brain alterations. It is well known that dietary intake influences the composition and diversity of the gut microbiota and that its disruption plays a central role in the development of obesity, chronic low-grade inflammation, insulin resistance and cardiovascular disease. Some studies have reported improvements in blood pressure, lipid profile, glucose homeostasis, endothelial function, arterial stiffness and inflammation following cranberry consumption, but others found no significant changes. A recent meta-analysis reported that taking a polyphenol-rich supplement is associated with improved cognitive function in young adults. Although the mechanisms underlying the beneficial effects of polyphenols on brain function and cognition remain to be elucidated, some studies suggest that these effects may be associated with their anti-inflammatory and antioxidant properties and their possible effect on the cerebrovascular system. To our knowledge, there are no randomized controlled studies that have evaluated the effects of polyphenol-rich cranberry extract standardized in PACs on neurometabolic and neurocognitive functions in participants with abdominal obesity. Objectives and Hypothesis: The objective of this double-blind, randomized placebo-controlled clinical trial is to evaluate the effects of consumption of polyphenol-rich cranberry extract standardized in PACs (36 mg PACs/capsule) on cardiometabolic and neurocognitive health in abdominally obese women and men over an 8-week period. The overall hypothesis is that standardized extract of PACs from cranberry improves the metabolic profiles in abdominally obese individuals and this will have a beneficial impact on brain and neurocognitive functions. Methodology: Sixty men and women with a BMI between 30 and 40 kg/m2 and an altered blood lipid profile (triglycerides) will be recruited at the IUCPQ-Université Laval via social networks and Laval University's recall lists. The study will include 3 visits to the IUCPQ-Université Laval as well as the consumption of a cranberry extract or a placebo at a rate of one capsule per day for 8 weeks (56 days). The eligibility visit (V1) consists of completing a medical history questionnaire, and anthropometric and fasting blood lipid measurements. Individuals eligible to participate will then be invited to 2 identical visits at the IUCPQ-Université Laval (V2 and V3). At visit 2, cognitive tasks, anthropometric measurements, blood pressure, MRI (Philips 3T) and a pan-body DXA will be performed in all participants. Cognitive function will be measured using a battery of validated neurocognitive tasks. On the morning of each MRI session, fasting blood samples will be collected. Stool samples will be collected by participants prior to each visit 2 and 3 to measure microbiota composition. Following visit 2, participants will leave with capsules of cranberry extract containing 36 mg of PACS or a placebo (double-blind randomization) and will be asked to consume one capsule per day for 56 consecutive days. They will return for the 3rd visit (identical to V2) 8 weeks after starting the supplements. Dietary and physical activity questionnaires will also be completed online before visits 2 and 3. At the beginning of the visits, any changes in the participant's health condition and use of medications and natural health products will be documented. A follow-up phone call will be scheduled with each participant on day 28 of the intervention to ensure that the intervention is going well. Adverse events related to supplementation will be documented. An end-of-study questionnaire will be completed by the participant at the last visit (V3) to confirm study blinding. Participants will be asked to report the remaining capsules at the last visit (V3), which will allow assessment of compliance with the intervention. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05062954
Study type Interventional
Source Laval University
Contact Andréanne Michaud, PhD
Phone 418-656-8711
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date September 2021
Completion date August 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04940962 - Translational Study Using Human Abdominal Adipose Tissue Biopsies to Investigate the Role of Cannabinoid Receptor 1 (CB1) in Controlling Endocannabinoid and Adipokine Secretion N/A
Completed NCT02194504 - The Belly Fat Study: Nutritional Intervention to Improve Metabolic Health in Subjects With Increased Abdominal Adiposity N/A
Completed NCT00374218 - Effect of Replacing HFCS With Sucromalt in Subjects With Raised Waist Circumference Phase 2
Completed NCT00520858 - Effects of Exercise Modality on Abdominal Obesity and Health Risk Factors in Older Men and Women N/A
Recruiting NCT03212391 - WAVE Study- Walking and Aging in VErona Study N/A
Completed NCT03898518 - The Effects of a Jump Rope Exercise Program on Body Composition and Self-efficacy in Obese Adolescent Girls N/A
Recruiting NCT04136717 - Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery N/A
Completed NCT01472666 - Dairy Lipids, Proteins, and the Metabolic Syndrome - "DairyHealth" N/A
Completed NCT00990457 - Evaluating the Effects Two Diets Combined With Exercise in Persons With Abdominal Obesity (The SHAPE5 Study) Phase 3
Completed NCT03773900 - Characterization of Gut Microbiota Composition and Activity After a Daily Supplementation of 4.5 g/Day of ChitinGlucan Fibre During 3 Weeks in At-cardiometabolic Risk Volunteers N/A
Completed NCT04635332 - Food Literacy and Physical Activity Intervention to Optimize Metabolic Health Among Women in Urban Uganda N/A
Completed NCT00739180 - Physical Activity in Youth: Implications for Reversing Risk Factors for Type 2 Diabetes N/A
Completed NCT00664729 - Diet, Exercise, Metabolism, and Obesity in Older Women N/A
Completed NCT03389425 - Application of the SIMPLE Program for Weight Loss at Pathways to Housing: A Feasibility Study N/A
Recruiting NCT04894526 - Alternating Energy Intake and Blood Fat Content After a Meal N/A
Completed NCT02931630 - The Effect of Whey Protein and Dietary Fibers on Risk Markers of the Metabolic Syndrome and Bone Health N/A
Completed NCT02772900 - Aging, Nitrate, Endothelial Function and Muscle Oxygenation N/A
Completed NCT01488409 - Effects of Acipimox on Mitochondrial Function in Obesity Phase 2
Completed NCT00893646 - Effects of Weight Reduction on Sleep and Alertness in Long-distance Truck and Bus Drivers N/A
Completed NCT01068626 - Rosuvastatin in Visceral Adiposity Phase 3